Skip to main content
Top
Published in: Molecular Cancer 1/2010

Open Access 01-12-2010 | Research

Over-expression of eukaryotic translation initiation factor 4 gamma 1 correlates with tumor progression and poor prognosis in nasopharyngeal carcinoma

Authors: Luxia Tu, Zhen Liu, Xiufang He, Ying He, Huiling Yang, Qingping Jiang, Siming Xie, Guanghui Xiao, Xin Li, Kaitai Yao, Weiyi Fang

Published in: Molecular Cancer | Issue 1/2010

Login to get access

Abstract

Background

The aim of the present study was to analyze the expression of eukaryotic translation initiation factor 4 gamma 1 (EIF4G1) in nasopharyngeal carcinoma (NPC) and its correlation with clinicopathologic features, including patients' survival time.

Methods

Using real-time PCR, we detected the expression of EIF4G1 in normal nasopharyngeal tissues, immortalized nasopharyngeal epithelial cell lines NP69, NPC tissues and cell lines. EIF4G1 protein expression in NPC tissues was examined using immunohistochemistry. Survival analysis was performed using Kaplan-Meier method. The effect of EIF4G1 on cell invasion and tumorigenesis were investigated.

Results

The expression levels of EIF4G1 mRNA were significantly greater in NPC tissues and cell lines than those in the normal nasopharyngeal tissues and NP69 cells (P < 0.001). Immunohistochemical analysis revealed that the expression of EIF4G1 protein was higher in NPC tissues than that in the nasopharyngeal tissues (P < 0.001). In addition, the levels of EIF4G1 protein in tumors were positively correlated with tumor T classification (P = 0.039), lymph node involvement (N classification, P = 0.008), and the clinical stages (P = 0.003) of NPC patients. Patients with higher EIF4G 1 expression had shorter overall survival time (P = 0.019). Multivariate analysis showed that EIF4G1 expression was an independent prognostic indicator for the overall survival of NPC patients. Using shRNA to knock down the expression of EIF4G1 not only markedly inhibited cell cycle progression, proliferation, migration, invasion, and colony formation, but also dramatically suppressed in vivo xenograft tumor growth.

Conclusion

Our data suggest that EIF4G1 can serve as a biomarker for the prognosis of NPC patients.
Appendix
Available only for authorised users
Literature
2.
go back to reference Chou J, Lin YC, Kim J, You L, Xu Z, He B, Jablons DM: Nasopharyngeal carcinoma--review of the molecular mechanisms of tumorigenesis. Head Neck. 2008, 30: 946-963. 10.1002/hed.20833PubMedCentralCrossRefPubMed Chou J, Lin YC, Kim J, You L, Xu Z, He B, Jablons DM: Nasopharyngeal carcinoma--review of the molecular mechanisms of tumorigenesis. Head Neck. 2008, 30: 946-963. 10.1002/hed.20833PubMedCentralCrossRefPubMed
3.
go back to reference Ozyar E, Ayhan A, Korcum AF, Atahan IL: Prognostic role of Epstein-Barr virus latent membrane protein-1 and interleukin-10 expression in patients with nasopharyngeal carcinoma. Cancer Invest. 2004, 22: 483-491. 10.1081/CNV-200026386CrossRefPubMed Ozyar E, Ayhan A, Korcum AF, Atahan IL: Prognostic role of Epstein-Barr virus latent membrane protein-1 and interleukin-10 expression in patients with nasopharyngeal carcinoma. Cancer Invest. 2004, 22: 483-491. 10.1081/CNV-200026386CrossRefPubMed
4.
go back to reference Liu LT, Peng JP, Chang HC, Hung WC: RECK is a target of Epstein-Barr virus latent membrane protein 1. Oncogene. 2003, 22: 8263-8270. 10.1038/sj.onc.1207157CrossRefPubMed Liu LT, Peng JP, Chang HC, Hung WC: RECK is a target of Epstein-Barr virus latent membrane protein 1. Oncogene. 2003, 22: 8263-8270. 10.1038/sj.onc.1207157CrossRefPubMed
5.
go back to reference Hsiao JR, Chang KC, Chen CW, Wu SY, Su IJ, Hsu MC, Jin YT, Tsai ST, Takada K, Chang Y: Endoplasmic reticulum stress triggers XBP-1-mediated up-regulation of an EBV oncoprotein in nasopharyngeal carcinoma. Cancer Res. 2009, 69: 4461-4467. 10.1158/0008-5472.CAN-09-0277CrossRefPubMed Hsiao JR, Chang KC, Chen CW, Wu SY, Su IJ, Hsu MC, Jin YT, Tsai ST, Takada K, Chang Y: Endoplasmic reticulum stress triggers XBP-1-mediated up-regulation of an EBV oncoprotein in nasopharyngeal carcinoma. Cancer Res. 2009, 69: 4461-4467. 10.1158/0008-5472.CAN-09-0277CrossRefPubMed
6.
go back to reference Ambrosini G, Adida C, Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997, 3: 917-921. 10.1038/nm0897-917CrossRefPubMed Ambrosini G, Adida C, Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997, 3: 917-921. 10.1038/nm0897-917CrossRefPubMed
7.
go back to reference Fang W, Li X, Jiang Q, Liu Z, Yang H, Wang S, Xie S, Liu Q, Liu T, Huang J: Transcriptional patterns, biomarkers and pathways characterizing nasopharyngeal carcinoma of Southern China. J Transl Med. 2008, 6: 32. 10.1186/1479-5876-6-32PubMedCentralCrossRefPubMed Fang W, Li X, Jiang Q, Liu Z, Yang H, Wang S, Xie S, Liu Q, Liu T, Huang J: Transcriptional patterns, biomarkers and pathways characterizing nasopharyngeal carcinoma of Southern China. J Transl Med. 2008, 6: 32. 10.1186/1479-5876-6-32PubMedCentralCrossRefPubMed
8.
go back to reference Jiang W, Liao Y, Zhao S, Wu B, Zhou R, Wei R, Zhang J, He Y, Wu H: Role of enhanced radiosensitivity and the tumor-specific suicide gene vector in gene therapy of nasopharyngeal carcinoma. J Radiat Res (Tokyo). 2007, 48: 211-218. 10.1269/jrr.06056CrossRef Jiang W, Liao Y, Zhao S, Wu B, Zhou R, Wei R, Zhang J, He Y, Wu H: Role of enhanced radiosensitivity and the tumor-specific suicide gene vector in gene therapy of nasopharyngeal carcinoma. J Radiat Res (Tokyo). 2007, 48: 211-218. 10.1269/jrr.06056CrossRef
9.
go back to reference Prevot D, Decimo D, Herbreteau CH, Roux F, Garin J, Darlix JL, Ohlmann T: Characterization of a novel RNA-binding region of eIF4GI critical for ribosomal scanning. EMBO J. 2003, 22: 1909-1921. 10.1093/emboj/cdg175PubMedCentralCrossRefPubMed Prevot D, Decimo D, Herbreteau CH, Roux F, Garin J, Darlix JL, Ohlmann T: Characterization of a novel RNA-binding region of eIF4GI critical for ribosomal scanning. EMBO J. 2003, 22: 1909-1921. 10.1093/emboj/cdg175PubMedCentralCrossRefPubMed
10.
go back to reference Braunstein S, Karpisheva K, Pola C, Goldberg J, Hochman T, Yee H, Cangiarella J, Arju R, Formenti SC, Schneider RJ: A hypoxia-controlled cap-dependent to cap-independent translation switch in breast cancer. Mol Cell. 2007, 28: 501-512. 10.1016/j.molcel.2007.10.019CrossRefPubMed Braunstein S, Karpisheva K, Pola C, Goldberg J, Hochman T, Yee H, Cangiarella J, Arju R, Formenti SC, Schneider RJ: A hypoxia-controlled cap-dependent to cap-independent translation switch in breast cancer. Mol Cell. 2007, 28: 501-512. 10.1016/j.molcel.2007.10.019CrossRefPubMed
11.
go back to reference Fukuchi-Shimogori T, Ishii I, Kashiwagi K, Mashiba H, Ekimoto H, Igarashi K: Malignant transformation by overproduction of translation initiation factor eIF4G. Cancer Res. 1997, 57: 5041-5044.PubMed Fukuchi-Shimogori T, Ishii I, Kashiwagi K, Mashiba H, Ekimoto H, Igarashi K: Malignant transformation by overproduction of translation initiation factor eIF4G. Cancer Res. 1997, 57: 5041-5044.PubMed
12.
go back to reference Prevot D, Darlix JL, Ohlmann T: Conducting the initiation of protein synthesis: the role of eIF4G. Biol Cell. 2003, 95: 141-156. 10.1016/S0248-4900(03)00031-5CrossRefPubMed Prevot D, Darlix JL, Ohlmann T: Conducting the initiation of protein synthesis: the role of eIF4G. Biol Cell. 2003, 95: 141-156. 10.1016/S0248-4900(03)00031-5CrossRefPubMed
13.
go back to reference Cromer A, Carles A, Millon R, Ganguli G, Chalmel F, Lemaire F, Young J, Dembele D, Thibault C, Muller D: Identification of genes associated with tumorigenesis and metastatic potential of hypopharyngeal cancer by microarray analysis. Oncogene. 2004, 23: 2484-2498. 10.1038/sj.onc.1207345CrossRefPubMed Cromer A, Carles A, Millon R, Ganguli G, Chalmel F, Lemaire F, Young J, Dembele D, Thibault C, Muller D: Identification of genes associated with tumorigenesis and metastatic potential of hypopharyngeal cancer by microarray analysis. Oncogene. 2004, 23: 2484-2498. 10.1038/sj.onc.1207345CrossRefPubMed
14.
go back to reference Comtesse N, Keller A, Diesinger I, Bauer C, Kayser K, Huwer H, Lenhof HP, Meese E: Frequent overexpression of the genes FXR1, CLAPM1 and EIF4G located on amplicon 3q26-27 in squamous cell carcinoma of the lung. Int J Cancer. 2007, 120: 2538-2544. 10.1002/ijc.22585CrossRefPubMed Comtesse N, Keller A, Diesinger I, Bauer C, Kayser K, Huwer H, Lenhof HP, Meese E: Frequent overexpression of the genes FXR1, CLAPM1 and EIF4G located on amplicon 3q26-27 in squamous cell carcinoma of the lung. Int J Cancer. 2007, 120: 2538-2544. 10.1002/ijc.22585CrossRefPubMed
15.
go back to reference Silvera D, Arju R, Darvishian F, Levine PH, Zolfaghari L, Goldberg J, Hochman T, Formenti SC, Schneider RJ: Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer. Nat Cell Biol. 2009, 11: 903-908. 10.1038/ncb1900CrossRefPubMed Silvera D, Arju R, Darvishian F, Levine PH, Zolfaghari L, Goldberg J, Hochman T, Formenti SC, Schneider RJ: Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer. Nat Cell Biol. 2009, 11: 903-908. 10.1038/ncb1900CrossRefPubMed
16.
go back to reference Bauer C, Brass N, Diesinger I, Kayser K, Grasser FA, Meese E: Overexpression of the eukaryotic translation initiation factor 4G (eIF4G-1) in squamous cell lung carcinoma. Int J Cancer. 2002, 98: 181-185. 10.1002/ijc.10180CrossRefPubMed Bauer C, Brass N, Diesinger I, Kayser K, Grasser FA, Meese E: Overexpression of the eukaryotic translation initiation factor 4G (eIF4G-1) in squamous cell lung carcinoma. Int J Cancer. 2002, 98: 181-185. 10.1002/ijc.10180CrossRefPubMed
17.
go back to reference Song LB, Yan J, Jian SW, Zhang L, Li MZ, Li D, Wang HM: [Molecular mechanisms of tumorgenesis and metastasis in nasopharyngeal carcinoma cell sublines]. Ai Zheng. 2002, 21: 158-162.PubMed Song LB, Yan J, Jian SW, Zhang L, Li MZ, Li D, Wang HM: [Molecular mechanisms of tumorgenesis and metastasis in nasopharyngeal carcinoma cell sublines]. Ai Zheng. 2002, 21: 158-162.PubMed
18.
go back to reference Liu T, Ding Y, Xie W, Li Z, Bai X, Li X, Fang W, Ren C, Wang S, Hoffman RM, Yao K: An imageable metastatic treatment model of nasopharyngeal carcinoma. Clin Cancer Res. 2007, 13: 3960-3967. 10.1158/1078-0432.CCR-07-0089CrossRefPubMed Liu T, Ding Y, Xie W, Li Z, Bai X, Li X, Fang W, Ren C, Wang S, Hoffman RM, Yao K: An imageable metastatic treatment model of nasopharyngeal carcinoma. Clin Cancer Res. 2007, 13: 3960-3967. 10.1158/1078-0432.CCR-07-0089CrossRefPubMed
19.
go back to reference Zakowicz H, Yang HS, Stark C, Wlodawer A, Laronde-Leblanc N, Colburn NH: Mutational analysis of the DEAD-box RNA helicase eIF4AII characterizes its interaction with transformation suppressor Pdcd4 and eIF4GI. RNA. 2005, 11: 261-274. 10.1261/rna.7191905PubMedCentralCrossRefPubMed Zakowicz H, Yang HS, Stark C, Wlodawer A, Laronde-Leblanc N, Colburn NH: Mutational analysis of the DEAD-box RNA helicase eIF4AII characterizes its interaction with transformation suppressor Pdcd4 and eIF4GI. RNA. 2005, 11: 261-274. 10.1261/rna.7191905PubMedCentralCrossRefPubMed
20.
go back to reference Yoshida M, Tomitori H, Machi Y, Hagihara M, Higashi K, Goda H, Ohya T, Niitsu M, Kashiwagi K, Igarashi K: Acrolein toxicity: Comparison with reactive oxygen species. Biochem Biophys Res Commun. 2009, 378: 313-318. 10.1016/j.bbrc.2008.11.054CrossRefPubMed Yoshida M, Tomitori H, Machi Y, Hagihara M, Higashi K, Goda H, Ohya T, Niitsu M, Kashiwagi K, Igarashi K: Acrolein toxicity: Comparison with reactive oxygen species. Biochem Biophys Res Commun. 2009, 378: 313-318. 10.1016/j.bbrc.2008.11.054CrossRefPubMed
21.
go back to reference Averous J, Proud CG: When translation meets transformation: the mTOR story. Oncogene. 2006, 25: 6423-6435. 10.1038/sj.onc.1209887CrossRefPubMed Averous J, Proud CG: When translation meets transformation: the mTOR story. Oncogene. 2006, 25: 6423-6435. 10.1038/sj.onc.1209887CrossRefPubMed
22.
go back to reference Moerke NJ, Aktas H, Chen H, Cantel S, Reibarkh MY, Fahmy A, Gross JD, Degterev A, Yuan J, Chorev M: Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell. 2007, 128: 257-267. 10.1016/j.cell.2006.11.046CrossRefPubMed Moerke NJ, Aktas H, Chen H, Cantel S, Reibarkh MY, Fahmy A, Gross JD, Degterev A, Yuan J, Chorev M: Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell. 2007, 128: 257-267. 10.1016/j.cell.2006.11.046CrossRefPubMed
23.
go back to reference Chung J, Bachelder RE, Lipscomb EA, Shaw LM, Mercurio AM: Integrin (alpha 6 beta 4) regulation of eIF-4E activity and VEGF translation: a survival mechanism for carcinoma cells. J Cell Biol. 2002, 158: 165-174. 10.1083/jcb.200112015PubMedCentralCrossRefPubMed Chung J, Bachelder RE, Lipscomb EA, Shaw LM, Mercurio AM: Integrin (alpha 6 beta 4) regulation of eIF-4E activity and VEGF translation: a survival mechanism for carcinoma cells. J Cell Biol. 2002, 158: 165-174. 10.1083/jcb.200112015PubMedCentralCrossRefPubMed
24.
go back to reference Wei N, Liu SS, Leung TH, Tam KF, Liao XY, Cheung AN, Chan KK, Ngan HY: Loss of Programmed cell death 4 (Pdcd4) associates with the progression of ovarian cancer. Mol Cancer. 2009, 8: 70. 10.1186/1476-4598-8-70PubMedCentralCrossRefPubMed Wei N, Liu SS, Leung TH, Tam KF, Liao XY, Cheung AN, Chan KK, Ngan HY: Loss of Programmed cell death 4 (Pdcd4) associates with the progression of ovarian cancer. Mol Cancer. 2009, 8: 70. 10.1186/1476-4598-8-70PubMedCentralCrossRefPubMed
25.
go back to reference Sun Z, Yang P, Aubry MC, Kosari F, Endo C, Molina J, Vasmatzis G: Can gene expression profiling predict survival for patients with squamous cell carcinoma of the lung?. Mol Cancer. 2004, 3: 35. 10.1186/1476-4598-3-35PubMedCentralCrossRefPubMed Sun Z, Yang P, Aubry MC, Kosari F, Endo C, Molina J, Vasmatzis G: Can gene expression profiling predict survival for patients with squamous cell carcinoma of the lung?. Mol Cancer. 2004, 3: 35. 10.1186/1476-4598-3-35PubMedCentralCrossRefPubMed
26.
go back to reference Yang HS, Jansen AP, Komar AA, Zheng X, Merrick WC, Costes S, Lockett SJ, Sonenberg N, Colburn NH: The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation. Mol Cell Biol. 2003, 23: 26-37. 10.1128/MCB.23.1.26-37.2003PubMedCentralCrossRefPubMed Yang HS, Jansen AP, Komar AA, Zheng X, Merrick WC, Costes S, Lockett SJ, Sonenberg N, Colburn NH: The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation. Mol Cell Biol. 2003, 23: 26-37. 10.1128/MCB.23.1.26-37.2003PubMedCentralCrossRefPubMed
27.
go back to reference Zhang S, Li J, Jiang Y, Xu Y, Qin C: Programmed cell death 4 (PDCD4) suppresses metastastic potential of human hepatocellular carcinoma cells. J Exp Clin Cancer Res. 2009, 28: 71. 10.1186/1756-9966-28-71PubMedCentralCrossRefPubMed Zhang S, Li J, Jiang Y, Xu Y, Qin C: Programmed cell death 4 (PDCD4) suppresses metastastic potential of human hepatocellular carcinoma cells. J Exp Clin Cancer Res. 2009, 28: 71. 10.1186/1756-9966-28-71PubMedCentralCrossRefPubMed
28.
go back to reference Xie SM, Fang WY, Liu Z, Wang SX, Li X, Liu TF, Xie WB, Yao KT: Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008, 6: 55- 10.1186/1479-5876-6-55PubMedCentralCrossRefPubMed Xie SM, Fang WY, Liu Z, Wang SX, Li X, Liu TF, Xie WB, Yao KT: Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008, 6: 55- 10.1186/1479-5876-6-55PubMedCentralCrossRefPubMed
29.
go back to reference Wang S, Zhou J, Wang XY, Hao JM, Chen JZ, Zhang XM, Jin H, Liu L, Zhang YF, Liu J: Down-regulated expression of SATB2 is associated with metastasis and poor prognosis in colorectal cancer. J Pathol. 2009, 219: 114-122. 10.1002/path.2575CrossRefPubMed Wang S, Zhou J, Wang XY, Hao JM, Chen JZ, Zhang XM, Jin H, Liu L, Zhang YF, Liu J: Down-regulated expression of SATB2 is associated with metastasis and poor prognosis in colorectal cancer. J Pathol. 2009, 219: 114-122. 10.1002/path.2575CrossRefPubMed
30.
go back to reference Masunaga R, Kohno H, Dhar DK, Ohno S, Shibakita M, Kinugasa S, Yoshimura H, Tachibana M, Kubota H, Nagasue N: Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res. 2000, 6: 4064-4068.PubMed Masunaga R, Kohno H, Dhar DK, Ohno S, Shibakita M, Kinugasa S, Yoshimura H, Tachibana M, Kubota H, Nagasue N: Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res. 2000, 6: 4064-4068.PubMed
31.
go back to reference Tu LX, Fang WY, Liu Z, Li X, He Y, Xie SM, Yao KT: [Establishment of a stable nasopharyngeal carcinoma cell line with lentivirus-mediated RNA interference for EIF4G1 gene silencing]. Nan Fang Yi Ke Da Xue Xue Bao. 2009, 29: 844-847. 851.PubMed Tu LX, Fang WY, Liu Z, Li X, He Y, Xie SM, Yao KT: [Establishment of a stable nasopharyngeal carcinoma cell line with lentivirus-mediated RNA interference for EIF4G1 gene silencing]. Nan Fang Yi Ke Da Xue Xue Bao. 2009, 29: 844-847. 851.PubMed
Metadata
Title
Over-expression of eukaryotic translation initiation factor 4 gamma 1 correlates with tumor progression and poor prognosis in nasopharyngeal carcinoma
Authors
Luxia Tu
Zhen Liu
Xiufang He
Ying He
Huiling Yang
Qingping Jiang
Siming Xie
Guanghui Xiao
Xin Li
Kaitai Yao
Weiyi Fang
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2010
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-9-78

Other articles of this Issue 1/2010

Molecular Cancer 1/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine